We use cookies to customise content for your subscription and for analytics.
If you continue to browse Lexology, we will assume that you are happy to receive all our cookies. For further information please read our Cookie Policy.
In cooperation with Association of Corporate Counsel
  Request new password

Search results

Order by most recent / most popular / relevance

Results: 1-10 of 107

Federal Circuit says certain human genes may be patented

  • Shook Hardy & Bacon LLP
  • -
  • USA
  • -
  • August 4 2011

In a ruling likely to be appealed to the U.S. Supreme Court, a divided Federal Circuit Court of Appeals panel has determined that genetic discoveries may, to a certain extent, be patented

Pharma trade group seeks biologics data exclusivity for international trade

  • Shook Hardy & Bacon LLP
  • -
  • USA
  • -
  • May 19 2011

PhRMA has reportedly called for the U.S. Trade Representative to go outside provisions in the Korea-U.S. trade deal (KORUS) and press for a 12-year period of exclusivity for biologics in ongoing Trans-Pacific Partnerships (TPP) negotiations

Fractured Myriad Genetics ruling follows SCOTUS remand

  • Shook Hardy & Bacon LLP
  • -
  • USA
  • -
  • August 30 2012

Ruling that one plaintiff had standing to seek a declaratory judgment as to the patent eligibility of certain genetic discoveries, the Federal Circuit Court of Appeals has once again reversed in part and affirmed in part a lower court’s determination that isolated DNA molecules and methods of comparing molecules to determine whether a patient’s genes have mutations that could cause breast and ovarian cancer were not patent eligible

$10-million prize offered for accurate human genome sequencing

  • Shook Hardy & Bacon LLP
  • -
  • USA
  • -
  • November 3 2011

Craig Venter, creator of rapid DNA sequencing technology, has reportedly told Scientific American that he and two partners will award $10 million to the first team that can meet “medical grade” accuracy in human genome sequencing, a factor that has been lacking since the technology was first developed in 2000

News bytes 10 January 2013

  • Shook Hardy & Bacon LLP
  • -
  • USA
  • -
  • January 10 2013

The U.S. Patent and Trademark Office (USPTO) schedules an Additive Manufacturing Partnership Meeting on January 23, 2013, at its Alexandria, Virginia

Exhaustion doctrine applied to method patent

  • Shook Hardy & Bacon LLP
  • -
  • USA
  • -
  • November 21 2013

A divided Federal Circuit Court of Appeals panel has determined that a method patent holder that gave away 60 percent of the blood-glucose testing

Science publisher claims submission of prior art to USPTO involves copyright infringement

  • Shook Hardy & Bacon LLP
  • -
  • USA
  • -
  • March 15 2012

A New Jersey-based publishing company has filed copyright infringement lawsuits in federal courts in two states against law firms that submitted citations to or copies of copyrighted articles from scientific journals to the U.S. Patent and Trademark Office (USPTO) with their clients’ patent applications

News bytes

  • Shook Hardy & Bacon LLP
  • -
  • USA
  • -
  • October 30 2014

The U.S. Food and Drug Administration (FDA) makes available Guidance for Industry titled "Circumstances that Constitute Delaying, Denying, Limiting

FTC reports “pay-for-delay” deal trend continuing

  • Shook Hardy & Bacon LLP
  • -
  • USA
  • -
  • November 3 2011

The Federal Trade Commission (FTC) has found that the ongoing trend of drug companies settling claims filed by rival generic manufacturers with “pay-for-delay” deals is proceeding unabated

FTC report on Authorized Generic Drugs generates comment and concern

  • Shook Hardy & Bacon LLP
  • -
  • USA
  • -
  • September 22 2011

The Federal Trade Commission has released a report titled “Authorized Generic Drugs: Short-Term Effects and Long-Term Impact,” in which the agency concludes that “pay-for-delay” agreements between name-brand drug manufacturers and generic drug makers is “a practice that causes substantial consumer harm” by keeping drug prices high